These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23771104)

  • 1. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
    Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
    Moyle G; Boffito M; Stoehr A; Rieger A; Shen Z; Manhard K; Sheedy B; Hingorani V; Raney A; Nguyen M; Nguyen T; Ong V; Yeh LT; Quart B
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3170-8. PubMed ID: 20498326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects.
    Hanna GJ; Lalezari J; Hellinger JA; Wohl DA; Nettles R; Persson A; Krystal M; Lin P; Colonno R; Grasela DM
    Antimicrob Agents Chemother; 2011 Feb; 55(2):722-8. PubMed ID: 21078951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
    Gupta SK; McComsey GA; Lombaard J; Echevarría J; Orrell C; Avihingsanon A; Osiyemi O; Santoscoy M; Ray N; Stock DA; Joshi SR; Hanna GJ; Lataillade M
    Lancet HIV; 2016 Jan; 3(1):e13-22. PubMed ID: 26762988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, placebo-controlled single-ascending-dose study to evaluate the safety, tolerability and pharmacokinetics of the HIV nucleoside reverse transcriptase inhibitor, BMS-986001, in healthy subjects.
    Urata Y; Paintsil E; Cheng YC; Matsuda T; Sevinsky H; Hawthorne D; Bertz R; Hanna GJ; Grasela D; Hwang C
    J Clin Pharmacol; 2014 Jun; 54(6):657-64. PubMed ID: 24374821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects.
    Gruzdev B; Rakhmanova A; Doubovskaya E; Yakovlev A; Peeters M; Rinehart A; de Dier K; Baede-Van Dijk P; Parys W; van 't Klooster G
    AIDS; 2003 Nov; 17(17):2487-94. PubMed ID: 14600520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.
    Zala C; St Clair M; Dudas K; Kim J; Lou Y; White S; Piscitelli S; Dumont E; Pietropaolo K; Zhou XJ; Mayers D
    Antimicrob Agents Chemother; 2012 May; 56(5):2570-5. PubMed ID: 22314532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
    Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
    AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
    Goebel F; Yakovlev A; Pozniak AL; Vinogradova E; Boogaerts G; Hoetelmans R; de Béthune MP; Peeters M; Woodfall B
    AIDS; 2006 Aug; 20(13):1721-6. PubMed ID: 16931936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients.
    Thompson MA; Kessler HA; Eron JJ; Jacobson JM; Adda N; Shen G; Zong J; Harris J; Moxham C; Rousseau FS;
    AIDS; 2005 Oct; 19(15):1607-15. PubMed ID: 16184030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial.
    Schürmann D; Rudd DJ; Zhang S; De Lepeleire I; Robberechts M; Friedman E; Keicher C; Hüser A; Hofmann J; Grobler JA; Stoch SA; Iwamoto M; Matthews RP
    Lancet HIV; 2020 Mar; 7(3):e164-e172. PubMed ID: 31911147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
    Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
    AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults.
    Lalezari J; Thompson M; Kumar P; Piliero P; Davey R; Patterson K; Shachoy-Clark A; Adkison K; Demarest J; Lou Y; Berrey M; Piscitelli S
    AIDS; 2005 Sep; 19(14):1443-8. PubMed ID: 16135896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy.
    Girard PM; Pegram PS; Diquet B; Anderson R; Raffi F; Tubiana R; Sereni D; Boerner D
    J Acquir Immune Defic Syndr; 2000 Mar; 23(3):227-35. PubMed ID: 10839658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults.
    Gallant JE; Thompson M; DeJesus E; Voskuhl GW; Wei X; Zhang H; White K; Cheng A; Quirk E; Martin H
    J Acquir Immune Defic Syndr; 2017 May; 75(1):61-66. PubMed ID: 28196003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor.
    Spreen W; Min S; Ford SL; Chen S; Lou Y; Bomar M; St Clair M; Piscitelli S; Fujiwara T
    HIV Clin Trials; 2013; 14(5):192-203. PubMed ID: 24144896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.
    Murphy RL; Kivel NM; Zala C; Ochoa C; Tharnish P; Mathew J; Pascual ML; Schinazi RF
    Antivir Ther; 2010; 15(2):185-92. PubMed ID: 20386073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
    Markowitz M; Morales-Ramirez JO; Nguyen BY; Kovacs CM; Steigbigel RT; Cooper DA; Liporace R; Schwartz R; Isaacs R; Gilde LR; Wenning L; Zhao J; Teppler H
    J Acquir Immune Defic Syndr; 2006 Dec; 43(5):509-15. PubMed ID: 17133211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects.
    Lalezari J; Gathe J; Brinson C; Thompson M; Cohen C; Dejesus E; Galindez J; Ernst JA; Martin DE; Palleja SM
    J Acquir Immune Defic Syndr; 2011 Jun; 57(2):118-25. PubMed ID: 21317794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.